Ask About Adherence: 3 factors impacting medication adherence for patients with diabetes and how our proactive affordability solutions can help
By Emilie Signora | July 20, 2021
Earlier this year, PhRMA released a proactive agenda with common-sense, patient-centered reforms to improve access to quality, affordable health care. The urgency of building a stronger, more...
Read More
New insulin report highlights how incentives benefit middlemen, harm patients
By Brian Newell | January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Sharing rebates can improve access to medicines and increase health equity
By Guest Contributor | September 30, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Guest post: H.R.3 is the wrong approach to help patients like me
By Guest Contributor | November 26, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Guest post: Sharing discounts and rebates is the right thing to do
By Guest Contributor | October 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New report shows more than 160 medicines in development for diabetes and related conditions
By Andrew Powaleny | April 24, 2019
Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5...
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
Six key facts about the market for insulins
By Holly Campbell | December 17, 2018
The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts...
Read More
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
By Guest Contributor | August 29, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH. ...
Read More
Reality check: Value-based contracts are good for patients
By Michelle Drozd | April 25, 2018
Biopharmaceutical companies are joining stakeholders across the health care system to pursue flexible ways to pay for medicines that focus on results, lower out-of-pocket costs and enable patients...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
